The results were based on the Quantitative Electroencephalogram study that was conducted in healthy individuals. Credit: YAKOBCHUK VIACHESLAV/Shutterstock.com.

Bright Minds Biosciences has reported positive results from Cohort 4 of its first-in-human Phase I study of BMB-101 to treat refractory epilepsies.

The lead compound BMB-101 is a highly selective and potent 5-HT2C agonist that is also indicated for treating addiction, psychosis, and impulse control disorders.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results were based on the Quantitative Electroencephalogram (qEEG) study that was conducted in healthy individuals in the multiple ascending dose arm.

Using qEEG power signature, central target engagement in the treatment group was easily identified in blinded data.

Significant reduction in central alpha and beta power, as well as an increase in central delta power were observed in the active group.

See Also:

An increased gamma frontal parietal connectivity in the treatment group was also observed, demonstrating an improved Anti-Epileptic Drug (AED) principle against benzodiazepine (GABAreceptor) AED drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, power and connectivity changes were concentration dependent.

The compound also showed significant safety and tolerability profile in the single ascending dose, multiple ascending dose and food effects parts of the study conducted in July this year.

Bright Minds CEO Ian McDonald said: “The positive topline findings from our recently completed Phase I study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate.

“BMB-101 is clearly [getting into the brain/achieving brain penetration] and activating the target receptors as we had predicted, setting us up for potential success in a number of indications that have been validated with the 5-HT2C mechanism.

“With this study complete, BMB-101 is now a Phase II ready asset, and we intend to move forward with an investigative new drug submission immediately.”